John D Reveille

List of Publications by Citations

196 papers	16,046 citations	61 h-index	124 g-index
207 ext. papers	18,336 ext. citations	5.6 avg, IF	6.29 L-index

#	Paper	IF	Citations
196	Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. *Arthritis and Rheumatism*, **2008**, 58, 15-25		1675
195	Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. *Nature Genetics*, **2007**, 39, 1329-37	36.3	1130
194	2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. *Annals of the Rheumatic Diseases*, **2017**, 76, 978-991	2.4	801
193	Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. *Nature Genetics*, **2011**, 43, 761-7	36.3	646
192	Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. *Arthritis and Rheumatism*, **2006**, 54, 2136-46		630
191	A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. *Nature Genetics*, **2009**, 41, 1228-33	36.3	626
190	Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. *Nature Genetics*, **2013**, 45, 730-8	36.3	551
189	Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. *Nature Genetics*, **2010**, 42, 123-7	36.3	484
188	Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. *Annals of the Rheumatic Diseases*, **2014**, 73, 6-16	2.4	308
187	The impact of tumor necrosis factor inhibitors on radiographic progression in ankylosing spondylitis. *Arthritis and Rheumatism*, **2013**, 65, 2645-54		301
186	American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. *Arthritis and Rheumatology*, **2016**, 68, 282-98	9.5	292
185	Systemic lupus erythematosus in three ethnic groups. VII [correction of VIII]. Predictors of early mortality in the LUMINA cohort. LUMINA Study Group. *Arthritis and Rheumatism*, **2001**, 45, 191-202		264
184	Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. *Arthritis and Rheumatism*, **2001**, 44, 1359-62		211
183	Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. *Arthritis and Rheumatism*, **2003**, 49, 399-412		196
182	Are there gender differences in severity of ankylosing spondylitis? Results from the PSOAS cohort. *Annals of the Rheumatic Diseases*, **2007**, 66, 633-8	2.4	184
181	Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. *Seminars in Arthritis and Rheumatism*, **2001**, 30, 332-46	5.3	184
180	Systemic lupus erythematosus in three ethnic groups: II. Features predictive of disease activity early in its course. LUMINA Study Group. Lupus in minority populations, nature versus nurture. *Arthritis and Rheumatism*, **1998**, 41, 1173-80		174

179	Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma. Association with an Amerindian HLA haplotype. *Arthritis and Rheumatism*, **1996**, 39, 1362-70		168
178	Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1. *Nature Communications*, **2015**, 6, 7146	17.4	164
177	Association of variants at 1q32 and STAT3 with ankylosing spondylitis suggests genetic overlap with Crohn's disease. *PLoS Genetics*, **2010**, 6, e1001195	6	162
176	Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. *Lancet, The*, **2018**, 392, 2441-2451	40	161
175	Immunochip analysis identifies multiple susceptibility loci for systemic sclerosis. *American Journal of Human Genetics*, **2014**, 94, 47-61	11	151
174	Prevalence of axial spondylarthritis in the United States: estimates from a cross-sectional survey. *Arthritis Care and Research*, **2012**, 64, 905-10	4.7	147
173	Genetics of spondyloarthritis--beyond the MHC. *Nature Reviews Rheumatology*, **2012**, 8, 296-304	8.1	142
172	Epidemiology of spondyloarthritis. *Rheumatic Disease Clinics of North America*, **2012**, 38, 441-76	2.4	140
171	Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis. *Arthritis and Rheumatism*, **1996**, 39, 1151-60		140
170	Interrelationship of major histocompatibility complex class II alleles and autoantibodies in four ethnic groups with various forms of myositis. *Arthritis and Rheumatism*, **1996**, 39, 1507-18		136
169	The clinical relevance of autoantibodies in scleroderma. *Arthritis Research*, **2003**, 5, 80-93		118
168	Association of the C8orf13-BLK region with systemic sclerosis in North-American and European populations. *Journal of Autoimmunity*, **2010**, 34, 155-62	15.5	108
167	Clinical, serologic, and immunogenetic studies in childhood-onset systemic lupus erythematosus. *Arthritis and Rheumatism*, **1993**, 36, 348-54		108
166	The epidemiology of back pain, axial spondyloarthritis and HLA-B27 in the United States. *American Journal of the Medical Sciences*, **2013**, 345, 431-6	2.2	107
165	The diffuse infiltrative lymphocytosis syndrome. *Aids*, **1996**, 10, 385-392	3.5	102
164	HLA-B27 and genetic predisposing factors in spondyloarthropathies. *Current Opinion in Rheumatology*, **2001**, 13, 265-72	5.3	102
163	Association of TNFSF4 (OX40L) polymorphisms with susceptibility to systemic sclerosis. *Annals of the Rheumatic Diseases*, **2010**, 69, 550-5	2.4	98
162	HLA-DPB1 and DPB2 are genetic loci for systemic sclerosis: a genome-wide association study in Koreans with replication in North Americans. *Arthritis and Rheumatism*, **2009**, 60, 3807-14		97

161	Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors. *Arthritis and Rheumatology*, **2019**, 71, 599-611	9.5	96
160	Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. *Arthritis and Rheumatism*, **2004**, 51, 800-4		94
159	Human immunodeficiency virus-associated psoriasis, psoriatic arthritis, and Reiter's syndrome: a disease continuum?. *Arthritis and Rheumatism*, **1990**, 33, 1574-8		94
158	Genetic studies in familial ankylosing spondylitis susceptibility. *Arthritis and Rheumatism*, **2004**, 50, 2246-54		93
157	The prevalence of HLA-B27 in the US: data from the US National Health and Nutrition Examination Survey, 2009. *Arthritis and Rheumatism*, **2012**, 64, 1407-11		92
156	Spondyloarthritis: update on pathogenesis and management. *American Journal of Medicine*, **2005**, 118, 592-603	2.4	90
155	The genetic contribution to the pathogenesis of rheumatoid arthritis. *Current Opinion in Rheumatology*, **1998**, 10, 187-200	5.3	90
154	Risk factors for functional limitations in patients with long-standing ankylosing spondylitis. *Arthritis and Rheumatism*, **2005**, 53, 710-7		88
153	Epidemiology of spondyloarthritis in North America. *American Journal of the Medical Sciences*, **2011**, 341, 284-6	2.2	87
152	Polymorphisms in TBX21 and STAT4 increase the risk of systemic sclerosis: evidence of possible gene-gene interaction and alterations in Th1/Th2 cytokines. *Arthritis and Rheumatism*, **2009**, 60, 3794-806		85
151	Human immunodeficiency virus-associated polymyositis: a longitudinal study of outcome. *Arthritis and Rheumatism*, **2003**, 49, 172-8		84
150	Association of an ERAP1 ERAP2 haplotype with familial ankylosing spondylitis. *Annals of the Rheumatic Diseases*, **2010**, 69, 733-6	2.4	83
149	The changing spectrum of rheumatic disease in human immunodeficiency virus infection. *Seminars in Arthritis and Rheumatism*, **2000**, 30, 147-66	5.3	82
148	A systemic sclerosis and systemic lupus erythematosus pan-meta-GWAS reveals new shared susceptibility loci. *Human Molecular Genetics*, **2013**, 22, 4021-9	5.6	81
147	Genetic dissection of acute anterior uveitis reveals similarities and differences in associations observed with ankylosing spondylitis. *Arthritis and Rheumatology*, **2015**, 67, 140-51	9.5	78
146	Major histocompatibility genes and ankylosing spondylitis. *Best Practice and Research in Clinical Rheumatology*, **2006**, 20, 601-9	5.3	74
145	The concept of axial spondyloarthritis: joint statement of the spondyloarthritis research and treatment network and the Assessment of SpondyloArthritis international Society in response to the US Food and Drug Administration's comments and concerns. *Arthritis and Rheumatology*, **2014**, 66, 2649-56	9.5	72
144	Prevalence of the diffuse infiltrative lymphocytosis syndrome among human immunodeficiency virus type 1-positive outpatients. *Arthritis and Rheumatism*, **1998**, 41, 863-8		68

143	IRF5 polymorphism predicts prognosis in patients with systemic sclerosis. *Annals of the Rheumatic Diseases*, **2012**, 71, 1197-202	2.4	66
142	The genetic basis of spondyloarthritis. *Annals of the Rheumatic Diseases*, **2011**, 70 Suppl 1, i44-50	2.4	65
141	Autoantibodies in systemic sclerosis and fibrosing syndromes: clinical indications and relevance. *Current Opinion in Rheumatology*, **2004**, 16, 723-32	5.3	65
140	Changing spectrum of the diffuse infiltrative lymphocytosis syndrome. *Arthritis and Rheumatism*, **2006**, 55, 466-72		64
139	ERAP2 is associated with ankylosing spondylitis in HLA-B27-positive and HLA-B27-negative patients. *Annals of the Rheumatic Diseases*, **2015**, 74, 1627-9	2.4	63
138	Women with ankylosing spondylitis: a review. *Arthritis and Rheumatism*, **2008**, 59, 449-54		62
137	Autoantibodies to fibrillin 1 in systemic sclerosis: ethnic differences in antigen recognition and lack of correlation with specific clinical features or HLA alleles. *Arthritis and Rheumatism*, **2000**, 43, 2464-71		62
136	Contrasting molecular patterns of MHC class II alleles associated with the anti-Sm and anti-RNP precipitin autoantibodies in systemic lupus erythematosus. *Arthritis and Rheumatism*, **1993**, 36, 94-104		62
135	Associations of anti-beta2-glycoprotein I autoantibodies with HLA class II alleles in three ethnic groups. *Arthritis and Rheumatism*, **1999**, 42, 268-74		60
134	Racial differences in the frequencies of scleroderma-related autoantibodies. *Arthritis and Rheumatism*, **1992**, 35, 216-8		60
133	Axial spondyloarthritis: a new disease entity, not necessarily early ankylosing spondylitis. *Annals of the Rheumatic Diseases*, **2013**, 72, 162-4	2.4	59
132	The prevalence of inflammatory back pain: population-based estimates from the US National Health and Nutrition Examination Survey, 2009-10. *Annals of the Rheumatic Diseases*, **2013**, 72, 369-73	2.4	59
131	HLA-D region genes associated with autoantibody responses to histidyl-transfer RNA synthetase (Jo-1) and other translation-related factors in myositis. *Arthritis and Rheumatism*, **1990**, 33, 1240-8		59
130	Occupational physical activities and long-term functional and radiographic outcomes in patients with ankylosing spondylitis. *Arthritis and Rheumatism*, **2008**, 59, 822-32		59
129	The genetic basis of autoantibody production. *Autoimmunity Reviews*, **2006**, 5, 389-98	13.6	57
128	Ethnicity and race and systemic sclerosis: how it affects susceptibility, severity, antibody genetics, and clinical manifestations. *Current Rheumatology Reports*, **2003**, 5, 160-7	4.9	57
127	Articular manifestations of human immunodeficiency virus infection. *Best Practice and Research in Clinical Rheumatology*, **2003**, 17, 265-87	5.3	57
126	Biomarkers for diagnosis, monitoring of progression, and treatment responses in ankylosing spondylitis and axial spondyloarthritis. *Clinical Rheumatology*, **2015**, 34, 1009-18	3.9	56

125	ANKH variants associated with ankylosing spondylitis: gender differences. *Arthritis Research*, **2005**, 7, R513-25		56
124	C-reactive protein as a marker of melanoma progression. *Journal of Clinical Oncology*, **2015**, 33, 1389-96	2.2	55
123	Infection and musculoskeletal conditions: Rheumatologic complications of HIV infection. *Best Practice and Research in Clinical Rheumatology*, **2006**, 20, 1159-79	5.3	55
122	Frequency of Axial Spondyloarthritis Diagnosis Among Patients Seen by US Rheumatologists for Evaluation of Chronic Back Pain. *Arthritis and Rheumatology*, **2016**, 68, 1669-76	9.5	55
121	Impact of ankylosing spondylitis on work and family life: comparisons with the US population. *Arthritis and Rheumatism*, **2008**, 59, 497-503		54
120	A locus on chromosome 9p predisposes to a specific disease manifestation, acute anterior uveitis, in ankylosing spondylitis, a genetically complex, multisystem, inflammatory disease. *Arthritis and Rheumatism*, **2005**, 52, 269-74		54
119	Novel genetic markers in the 5Rflanking region of ANKH are associated with ankylosing spondylitis. *Arthritis and Rheumatism*, **2003**, 48, 791-7		52
118	Association of Vitamin D Levels With Outcome in Patients With Melanoma After Adjustment For C-Reactive Protein. *Journal of Clinical Oncology*, **2016**, 34, 1741-7	2.2	49
117	Two functional lupus-associated BLK promoter variants control cell-type- and developmental-stage-specific transcription. *American Journal of Human Genetics*, **2014**, 94, 586-98	11	49
116	Rheumatic manifestations associated with HIV in the highly active antiretroviral therapy era. *Current Opinion in Rheumatology*, **2009**, 21, 404-10	5.3	49
115	Seasonal influence on the onset of idiopathic inflammatory myopathies in serologically defined groups. *Arthritis and Rheumatism*, **2005**, 52, 2433-8		47
114	The genetic basis of ankylosing spondylitis. *Current Opinion in Rheumatology*, **2006**, 18, 332-41	5.3	45
113	High-throughput single-nucleotide polymorphism analysis of the IL1RN locus in patients with ankylosing spondylitis by matrix-assisted laser desorption ionization-time-of-flight mass spectrometry. *Arthritis and Rheumatism*, **2003**, 48, 2011-8		45
112	DNA analysis of HLA-DR and DQ genes in American blacks with systemic lupus erythematosus. *Arthritis and Rheumatism*, **1989**, 32, 1243-51		45
111	Antinuclear antibody-negative systemic sclerosis. *Seminars in Arthritis and Rheumatism*, **2015**, 44, 680-6	5.3	43
110	Susceptibility to Reiter's syndrome is associated with alleles of TAP genes. *Arthritis and Rheumatism* , **1995**, 38, 684-9		43
109	CCL2 in the Circulation Predicts Long-Term Progression of Interstitial Lung Disease in Patients With Early Systemic Sclerosis: Data From Two Independent Cohorts. *Arthritis and Rheumatology*, **2017**, 69, 1871-1878	9.5	43
108	Psychological correlates of self-reported functional limitation in patients with ankylosing spondylitis. *Arthritis Research and Therapy*, **2009**, 11, R182	5.7	42

107	A missense mutation in the MLKL brace region promotes lethal neonatal inflammation and hematopoietic dysfunction. *Nature Communications*, **2020**, 11, 3150	17.4	41
106	The genetics of scleroderma (systemic sclerosis). *Current Opinion in Rheumatology*, **2010**, 22, 133-8	5.3	41
105	American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. *Arthritis Care and Research*, **2016**, 68, 151-66	4.7	39
104	Economic considerations of the treatment of ankylosing spondylitis. *American Journal of the Medical Sciences*, **2012**, 343, 371-4	2.2	35
103	Anti-scl-70. *Autoimmunity*, **2005**, 38, 65-72	3	35
102	The centromere kinesin-like protein, CENP-E. An autoantigen in systemic sclerosis. *Arthritis and Rheumatism*, **1996**, 39, 1355-61		35
101	Markers of intestinal inflammation in patients with ankylosing spondylitis: a pilot study. *Arthritis Research and Therapy*, **2012**, 14, R261	5.7	34
100	Therapy insight: the changing spectrum of rheumatic disease in HIV infection. *Nature Clinical Practice Rheumatology*, **2008**, 4, 428-38		34
99	An update on the contribution of the MHC to AS susceptibility. *Clinical Rheumatology*, **2014**, 33, 749-57	3.9	33
98	Preferential binding to Elk-1 by SLE-associated IL10 risk allele upregulates IL10 expression. *PLoS Genetics*, **2013**, 9, e1003870	6	33
97	Novel sequence feature variant type analysis of the HLA genetic association in systemic sclerosis. *Human Molecular Genetics*, **2010**, 19, 707-19	5.6	33
96	Subtypes of HLA-B27: history and implications in the pathogenesis of ankylosing spondylitis. *Advances in Experimental Medicine and Biology*, **2009**, 649, 159-76	3.6	33
95	MICA, a gene contributing strong susceptibility to ankylosing spondylitis. *Annals of the Rheumatic Diseases*, **2014**, 73, 1552-7	2.4	32
94	Psychological correlates of self-reported disease activity in ankylosing spondylitis. *Journal of Rheumatology*, **2010**, 37, 829-34	4.1	32
93	Recent studies on the genetic basis of ankylosing spondylitis. *Current Rheumatology Reports*, **2009**, 11, 340-8	4.9	32
92	Genetic studies of ankylosing spondylitis in Koreans confirm associations with ERAP1 and 2p15 reported in white patients. *Journal of Rheumatology*, **2011**, 38, 322-4	4.1	32
91	Lupus Risk Variant Increases pSTAT1 Binding and Decreases ETS1 Expression. *American Journal of Human Genetics*, **2015**, 96, 731-9	11	31
90	Anti-fibrillarin antibody in African American patients with systemic sclerosis: immunogenetics, clinical features, and survival analysis. *Journal of Rheumatology*, **2011**, 38, 1622-30	4.1	31

89	The contribution of genes outside the major histocompatibility complex to susceptibility to ankylosing spondylitis. *Current Opinion in Rheumatology*, **2008**, 20, 384-91	5.3	31
88	Major histocompatibility complex class II and C4 alleles in Mexican Americans with systemic lupus erythematosus. *Tissue Antigens*, **1995**, 45, 91-7		31
87	HLA class I and II alleles in susceptibility to ankylosing spondylitis. *Annals of the Rheumatic Diseases*, **2019**, 78, 66-73	2.4	31
86	HLA-DPB1 alleles and autoantibody subsets in systemic lupus erythematosus, Sjögren's syndrome and progressive systemic sclerosis: a question of disease relevance. *Tissue Antigens*, **1992**, 40, 45-8		29
85	The chromosome 16q region associated with ankylosing spondylitis includes the candidate gene tumour necrosis factor receptor type 1-associated death domain (TRADD). *Annals of the Rheumatic Diseases*, **2010**, 69, 1243-6	2.4	28
84	Association of the HLA-DRB1 with scleroderma in Chinese population. *PLoS ONE*, **2014**, 9, e106939	3.7	27
83	Malignant melanoma: relationship of the human leukocyte antigen class II gene DQB1*0301 to disease recurrence in American Joint Committee on Cancer Stage I or II. *Cancer*, **1996**, 78, 758-63	6.4	27
82	Association between Body Mass Index, C-Reactive Protein Levels, and Melanoma Patient Outcomes. *Journal of Investigative Dermatology*, **2017**, 137, 1792-1795	4.3	26
81	Safety and Efficacy of Golimumab Administered Intravenously in Adults with Ankylosing Spondylitis: Results through Week 28 of the GO-ALIVE Study. *Journal of Rheumatology*, **2018**, 45, 341-348	4.1	26
80	Clinical, immunologic, and genetic features of familial systemic sclerosis. *Arthritis and Rheumatism*, **2007**, 56, 2031-7		25
79	Systemic lupus erythematosus in three ethnic groups. V. Acculturation, health-related attitudes and behaviors, and disease activity in Hispanic patients from the LUMINA cohort. LUMINA Study Group. Lupus in Minority Populations, Nature versus Nurture. *Arthritis and Rheumatism*, **1999**, 12, 267-76		25
78	Genetic studies in the rheumatic diseases: present status and implications for the future. *Journal of rheumatology Supplement, The*, **2005**, 72, 10-3		23
77	Lupus risk variants in the PXK locus alter B-cell receptor internalization. *Frontiers in Genetics*, **2014**, 5, 450	4.5	22
76	A plausibly causal functional lupus-associated risk variant in the STAT1-STAT4 locus. *Human Molecular Genetics*, **2018**, 27, 2392-2404	5.6	22
75	Review of Current Workforce for Rheumatology in the Countries of the Americas 2012-2015. *Journal of Clinical Rheumatology*, **2016**, 22, 405-410	1.1	22
74	HLA-DR2-DRB1 allele frequencies in DR2-positive black Americans with and without systemic lupus erythematosus. *Tissue Antigens*, **1991**, 38, 178-80		22
73	Spondyloarthritis: clinical suspicion, diagnosis, and sports. *Current Sports Medicine Reports*, **2009**, 8, 29-34	1.9	21
72	Genomewide Association Study of Acute Anterior Uveitis Identifies New Susceptibility Loci **2020**, 61, 3		20

71	Ethnicity and disease severity in ankylosing spondylitis a cross-sectional analysis of three ethnic groups. *Clinical Rheumatology*, **2017**, 36, 2359-2364	3.9	19
70	Analysis of HLA-B15 and HLA-B27 in spondyloarthritis with peripheral and axial clinical patterns. *BMJ Open*, **2015**, 5, e009092	3	19
69	Lack of linkage of IL1RN genotypes with ankylosing spondylitis susceptibility. *Arthritis and Rheumatism*, **2004**, 50, 3047-8		19
68	Development and validation of a case ascertainment tool for ankylosing spondylitis. *Arthritis Care and Research*, **2010**, 62, 19-27	4.7	18
67	Association of a TNAP haplotype with ankylosing spondylitis. *Arthritis and Rheumatism*, **2007**, 56, 234-43		18
66	Profiling of hla-B alleles for association studies with ankylosing spondylitis in the chinese population. *Open Rheumatology Journal*, **2013**, 7, 51-4	0.2	18
65	Is there a higher genetic load of susceptibility loci in familial ankylosing spondylitis?. *Arthritis Care and Research*, **2012**, 64, 780-4	4.7	17
64	Molecular genetics of systemic sclerosis. *Current Opinion in Rheumatology*, **1995**, 7, 522-8	5.3	17
63	Regional radiographic damage and functional limitations in patients with ankylosing spondylitis: differences in early and late disease. *Arthritis Care and Research*, **2013**, 65, 257-65	4.7	16
62	The genetic basis of spondyloarthritis. *Current Rheumatology Reports*, **2004**, 6, 117-25	4.9	16
61	Gene-level association analysis of systemic sclerosis: A comparison of African-Americans and White populations. *PLoS ONE*, **2018**, 13, e0189498	3.7	15
60	Opioid Analgesic Use in Patients with Ankylosing Spondylitis: An Analysis of the Prospective Study of Outcomes in an Ankylosing Spondylitis Cohort. *Journal of Rheumatology*, **2018**, 45, 188-194	4.1	13
59	Decreased SMG7 expression associates with lupus-risk variants and elevated antinuclear antibody production. *Annals of the Rheumatic Diseases*, **2016**, 75, 2007-2013	2.4	12
58	New population-based reference values for spinal mobility measures based on the 2009-2010 National Health and Nutrition Examination Survey. *Arthritis and Rheumatology*, **2014**, 66, 2628-37	9.5	12
57	A dimorphic Alu Sb-like insertion in COL3A1 is ethnic-specific. *Journal of Molecular Evolution*, **1996**, 42, 117-23	3.1	12
56	The contribution of disease activity on functional limitations over time through psychological mediators: a 12-month longitudinal study in patients with ankylosing spondylitis. *Rheumatology*, **2011**, 50, 2087-92	3.9	11
55	Nonsteroidal Antiinflammatory Drug Use and Association With Incident Hypertension in Ankylosing Spondylitis. *Arthritis Care and Research*, **2020**, 72, 1645-1652	4.7	11
54	The Effect of HLA-B27 on Susceptibility and Severity of COVID-19. *Journal of Rheumatology*, **2021**, 48, 621-622	4.1	11

53	Epidemiology of ankylosing spondylitis: IGAS 2009. *Journal of Rheumatology*, **2010**, 37, 2624-5	4.1	10
52	Ankylosing spondylitis risk factors: a systematic literature review. *Clinical Rheumatology*, **2021**, 40, 3079-3093	3.9	10
51	Genetic association of non-MHC region with ankylosing spondylitis in a Chinese population. *Annals of the Rheumatic Diseases*, **2019**, 78, 852-853	2.4	9
50	Preferential association of a functional variant in complement receptor 2 with antibodies to double-stranded DNA. *Annals of the Rheumatic Diseases*, **2016**, 75, 242-52	2.4	8
49	Correlation of serum MMP3 and other biomarkers with clinical outcomes in patients with ankylosing spondylitis: a pilot study. *Clinical Rheumatology*, **2017**, 36, 1819-1826	3.9	8
48	Genetic associations of leptin-related polymorphisms with systemic lupus erythematosus. *Clinical Immunology*, **2015**, 161, 157-62	9	8
47	A multiple imputation method based on weighted quantile regression models for longitudinal censored biomarker data with missing values at early visits. *BMC Medical Research Methodology*, **2018**, 18, 8	4.7	8
46	Harmonization, data management, and statistical issues related to prospective multicenter studies in Ankylosing spondylitis (AS): Experience from the Prospective Study Of Ankylosing Spondylitis (PSOAS) cohort. *Contemporary Clinical Trials Communications*, **2018**, 11, 127-135	1.8	8
45	Polygenic Risk Scores have high diagnostic capacity in ankylosing spondylitis. *Annals of the Rheumatic Diseases*, **2021**, 80, 1168-1174	2.4	8
44	Safety and Efficacy of Intravenous Golimumab in Adults with Ankylosing Spondylitis: Results through 1 Year of the GO-ALIVE Study. *Journal of Rheumatology*, **2019**, 46, 1277-1283	4.1	7
43	Reliability and Validity of Patient-reported Outcomes Measurement Information System Short Forms in Ankylosing Spondylitis. *Journal of Rheumatology*, **2020**, 47, 1182-1188	4.1	7
42	A registry of ankylosing spondylitis registries and prospects for global interfacing. *Current Opinion in Rheumatology*, **2013**, 25, 468-76	5.3	7
41	A family-based genome-wide association study reveals an association of spondyloarthritis with MAPK14. *Annals of the Rheumatic Diseases*, **2017**, 76, 310-314	2.4	6
40	The IgG galactosylation ratio is higher in spondyloarthritis patients and associated with the MRI score. *Clinical Rheumatology*, **2020**, 39, 2317-2323	3.9	6
39	Functional limitations due to axial and peripheral joint impairments in patients with ankylosing spondylitis: are focused measures more informative?. *Arthritis Care and Research*, **2013**, 65, 607-14	4.7	6
38	Achievement of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Criteria for Systemic Lupus Erythematosus and Amount of Damage Accrual: Results From a Multiethnic Multicenter Cohort. *Arthritis Care and Research*, **2021**, 73, 1038-1040	4.7	6
37	Cauda Equina Syndrome in Ankylosing Spondylitis: Challenges in Diagnosis, Management, and Pathogenesis. *Journal of Rheumatology*, **2019**, 46, 1582-1588	4.1	5
36	Association of Common Genetic Polymorphisms with Melanoma Patient IL-12p40 Blood Levels, Risk, and Outcomes. *Journal of Investigative Dermatology*, **2015**, 135, 2266-2272	4.3	5

35	Malignant melanoma: relationship of the human leukocyte antigen Class II gene DQB1*0301 to disease recurrence in American Joint Committee on Cancer Stage I or II **1996**, 78, 758		5
34	Longitudinal associations between depressive symptoms and clinical factors in ankylosing spondylitis patients: analysis from an observational cohort. *Rheumatology International*, **2020**, 40, 1053-1061	3.6	4
33	Spondyloarthritis **2019**, 769-787		4
32	Smoking quantity determines disease activity and function in Chinese patients with ankylosing spondylitis. *Clinical Rheumatology*, **2018**, 37, 1605-1616	3.9	3
31	Spinal Radiographic Progression and Predictors of Progression in Patients With Radiographic Axial Spondyloarthritis Receiving Ixekizumab Over 2 Years. *Journal of Rheumatology*, **2021**,	4.1	3
30	Correspondence on ‘Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry’ *Annals of the Rheumatic Diseases*, **2021**,	2.4	3
29	The Interplay Between COVID-19 and Spondyloarthritis or Its Treatment. *Journal of Rheumatology*, **2021**,	4.1	3
28	Spondyloarthropathies: EULAR recommendations reflect advances in imaging. *Nature Reviews Rheumatology*, **2015**, 11, 388-9	8.1	2
27	The changing profile of ankylosing spondylitis in the biologic era. *Clinical Rheumatology*, **2020**, 39, 2641-2651	3.9	2
26	Melanoma Expression Genes Identified through Genome-Wide Association Study of Breslow Tumor Thickness. *Journal of Investigative Dermatology*, **2017**, 137, 253-257	4.3	2
25	Systemic lupus erythematosus in the setting of HIV-1 infection: a longitudinal analysis. *Clinical Rheumatology*, **2020**, 39, 413-418	3.9	2
24	Imputation-based analysis of MICA alleles in the susceptibility to ankylosing spondylitis. *Annals of the Rheumatic Diseases*, **2020**, 79, e1	2.4	2
23	Validation of the Ankylosing Spondylitis Quality of Life assessment tool in patients with non-radiographic axial spondyloarthritis. *Quality of Life Research*, **2021**, 30, 945-954	3.7	2
22	The effect of intravenous golimumab on health-related quality of life and work productivity in adult patients with active ankylosing spondylitis: results of the phase 3 GO-ALIVE trial. *Clinical Rheumatology*, **2021**, 40, 1331-1341	3.9	2
21	Identifying Trajectories of Radiographic Spinal Disease in Ankylosing Spondylitis: A 15-year follow up study of the PSOAS Cohort. *Rheumatology*, **2021**,	3.9	2
20	Development of an environmental contextual factor item set relevant to global functioning and health in patients with axial Spondyloarthritis. *Rheumatology*, **2021**,	3.9	2
19	Systemic lupus erythematosus in three ethnic groups: V. Acculturation, health-related attitudes and behaviors, and disease activity in Hispanic patients from the LUMINA Cohort **1999**, 12, 267		2
18	Prologue: 2009 Joint Meeting of Spondyloarthritis Research and Therapy Network (SPARTAN) and International Genetics of Ankylosing Spondylitis (IGAS). *Journal of Rheumatology*, **2010**, 37, 2604-5	4.1	1

17	Chronic back pain in first-degree relatives (FDRs) of patients with ankylosing spondylitis: predictive value of HLA-B27 and persistence of inflammatory back pain over time. *RMD Open*, **2020**, 6,	5.9	1
16	Biomarkers in axial spondyloarthritis and low back pain: a comprehensive review. *Clinical Rheumatology*, **2021**, 1	3.9	1
15	Spondyloarthritis **2008**, 837-857		1
14	Rheumatic Manifestations of Human Immunodeficiency Virus Infection **2017**, 1929-1942		1
13	Spondyloarthritis **2013**, 676-692		1
12	A latent class based imputation method under Bayesian quantile regression framework using asymmetric Laplace distribution for longitudinal medication usage data with intermittent missing values. *Journal of Biopharmaceutical Statistics*, **2020**, 30, 160-177	1.3	1
11	Content validity of the ASQoL for use in a non-radiographic axial spondyloarthritis population: a qualitative study. *Quality of Life Research*, **2020**, 29, 3155-3166	3.7	1
10	Single-cell analysis reveals innate immunity dynamics in ankylosing spondylitis. *Clinical and Translational Medicine*, **2021**, 11, e369	5.7	1
9	Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients with Ankylosing Spondylitis: 28-Week Results of the GO-ALIVE Trial. *Value in Health*, **2020**, 23, 1281-1285	3.3	0
8	HLA-B27 is associated with reduced disease activity in axial spondyloarthritis. *Scientific Reports*, **2021**, 11, 12331	4.9	0
7	Exome-Wide Association Analysis Suggests LRP2BP as a Susceptibility Gene for Endothelial Injury in Systemic Sclerosis in the Han Chinese Population. *Journal of Investigative Dermatology*, **2021**, 141, 1254-1263.e6	4.3	0
6	Update on the treatment of systemic lupus erythematosus. *Womens Health*, **2006**, 2, 605-16	3	
5	The Major Histocompatibility Complex and Reactive Arthritis **2019**, 355-372		
4	Statins Reduce Disease Activity (SLAM-R) and Organ Damage Accrual (SLICC Damage Index, SDI) Scores in SLE Patients From A Multi-Center, Multi-Ethnic, US Cohort.. *Blood*, **2009**, 114, 5066-5066	2.2	
3	Rheumatic Manifestations of Human Immunodeficiency Virus Infection **2013**, 1851-1864		
2	Repeated Spinal Mobility Measures and Their Association With Radiographic Damage in Ankylosing Spondylitis. *ACR Open Rheumatology*, **2021**, 3, 413-421	3.5	
1	Chronic inflammatory back pain commencing late in life: a neglected concept.. *Internal Medicine Journal*, **2022**, 52, 485-487	1.6	